Kirin saw the highest growth of 162% in patent filings in March and 232% in grants in February in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 51% and grants by 24%. GlobalData’s DataBook provides a comprehensive analysis of Kirin’s patent filings and grants. Buy the databook here.
Kirin has been focused on protecting inventions in European Patent Office(EPO) with 12 publications in Q1 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 24% of filings. The European Patent Office(EPO), United States(US), Australia(AU), and China(CN) patent Office are among the top ten patent offices where Kirin is filings its patents. Among the top granted patent authorities, Kirin has 24% of its grants in United States(US), 18% in China(CN) and 18% in Japan(JP).
F. Hoffmann-La Roche could be the strongest competitor for Kirin
Patents related to rare diseases and health & wellness lead Kirin's portfolio
Kirin has the highest number of patents in rare diseases followed by, health & wellness and climate change. For rare diseases, nearly 53% of patents were filed and 29% of patents were granted in Q1 2024.
Food related patents lead Kirin portfolio followed by petrochemicals, and inflammation
Kirin has highest number of patents in food followed by petrochemicals, inflammation, packaging, and non-alcoholic beverages. For food, nearly 15% of patents were filed and 18% of patents were granted in Q1 2024.
For comprehensive analysis of Kirin's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.